Company: WHWK
Filing Date: 2025-01-31
Form Type: DEFM14A
Source: 0001193125-25-018470
Chunk: 411

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-31
Form: DEFM14A
Chunk 411
---
 may develop. We are at risk that any such future collaborations may not be successful. Factors that may affect the success of our collaborations include the following:

| • |     | our collaboration partners may incur financial and cash flow difficulties that force them to limit or reduce 
 their efforts under their collaboration agreement with us;                                                   |

| • |     | our collaboration partners may be pursuing alternative technologies or developing alternative products that are 
 competitive to our technology and products, either on their own or in partnership with others;                  |

| • |     | our collaboration partners may terminate their collaboration with us, which could make it difficult for us to 
 attract new partners or adversely affect perception of us in the business and financial communities; and      |

| • |     | our collaboration partners may pursue higher priority programs or change the focus of their development programs, 
 which could affect their commitment to us.                                                                        |

In addition, any future collaboration agreements we may enter into, are generally subject to termination by the counterparty on short notice upon the occurrence of certain circumstances without cause subject to a specified notice period. Accordingly, even if we believe that the development of product candidates is worth pursuing, our partners may choose not to continue with such development. If any of our collaborations are terminated, we may not receive additional milestones or royalties under those collaborations. In addition, we may be required to devote additional resources to the development of our product candidates or seek a new collaboration partner on short notice, and the terms of any additional collaboration or other arrangements that we establish may not be favorable to us. Future efforts for additional alliances or collaborations may also require us to incur non-recurringand other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners, and the negotiation process is time-consuming and complex. Furthermore, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. We cannot be certain that, following a strategic transaction or license, we will achieve the revenues or specific net income that justifies such transaction. If we cannot maintain successful collaborations, our business, financial condition, and operating results may be adversely affected. - 280 -

If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. From time to time, we evaluate various